WHY: Making the world disease free. HOW: We find the real drug lead candidate by capturing the synergistic effect of mutations (epistasis). WHAT: We have developed the Data-Centric innov’SAR AI industrial platform for our partners. PEACCEL is definitely the ONLY company capable of fully capturing epistasis and predicting outside-the-box, we are ahead of competition especially in terms of "hit rate". We can solve the "1+1=10" challenge! The innov'SAR core approach is interpolative, extrapolative and predicts outside-of-the-box, not found in other state-of-the-art ML / DL. It can screen 1 billion mutants per day. PEACCEL can produce massive amounts of Synthetic data to train its ML/DL platform. Other companies have taken the shortcut of relying on existing datasets which are often messy and of low quality. PEACCEL is built around the 6 pillars - P6 -: PLATFORM, PUBLICATIONS, PATENTS, PARTNERSHIPS, PRODUCTS and PEOPLE We have developed the innov'SAR PLATFORM, including 4 modules : 1- innov’SAR core: For the optimization of polypeptides (peptides, proteins, enzymes, antibodies, VHHs) 2- RAS module: For evaluating combination of Drugs (FDCs) in various diseases 3- automlSAR: this tool tests in parallel >135 algorithms, is agnostic with respect to the data set and can be combined with innov’SAR core & RAS module 4- GraphMut: Graph-based visualization tool of relations between the mutations of protein sequence variants and activity variations 15 PUBLICATIONS in the last 2 years Strong worldwide PATENTS (on technology using FFT), with more to come Robust PARTNERSHIPS with top notch KOLs worldwide Focus on high value PRODUCTS Highly skilled PEOPLE in high-tech fields.
| Website | http://www.peaccel.com/ |
| Revenue | $7 million |
| Employees | 5 (4 on RocketReach) |
| Founded | 2016 |
| Technologies |
JavaScript
,
HTML
,
PHP
+13 more
(view full list)
|
| Industry | Biotechnology Research, Business Services General, Biotechnology, Business Services, Science and Engineering, Genetics, Health Care, Life Science, Product Design, Design, Therapeutics |
| Keywords | Drug Discovery, Disease Research, Ai Platform, Mutation Analysis, Biotechnology, Drug Development, Therapeutic Target Identification, Pharmaceutical Research, In Silico Drug Design, Machine Learning, Precision Medicine, Genomic Analysis, Bioinformatics, Computational Biology, Artificial Intelligence |
| Competitors | Microsoft, Oracle, Salesforce, SAP, Zoho, NetSuite, Sage, Deltek, Infor, Acumatica +40 more (view full list) |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 541714 Companies, NAICS Code 54171 Companies |
Looking for a particular PEACCEL employee's phone or email?
The PEACCEL annual revenue was $7 million in 2026.
Laurent Contaut is the CEO of PEACCEL.
4 people are employed at PEACCEL.
The NAICS codes for PEACCEL are [541, 5417, 54, 541714, 54171].
The SIC codes for PEACCEL are [873, 87].